All over the "ignition" Kangmei Pharmaceuticals half a year to throw more than 3 billion

On July 27th, Kangmei Pharmaceuticals, a leading Chinese medicine and beverage company, announced that, after consideration by the first interim shareholders' meeting in 2018, it had approved bills on investing in the construction of the Kangmei Puning Chinese Medicine Industrial Park project and the Kangmei Kunming Health Industrial Park project, which involved 1.6 billion yuan and 1.4 billion yuan, respectively. According to public statistics, in 2018 (statistics as of July 27, 2018), Kangmei Pharmaceutical Co., D.C., invested a total of more than 3 billion yuan in trade-related business of Chinese medicine tablets and Chinese herbal medicines in eight regions. According to the 2017 Annual Report, Comm pharmaceutical's Chinese medicine tablet business revenue reached 6.158 billion yuan, up 30.93 percent year-on-year, and the Chinese herbal medicine trade business revenue reached 5.857 billion yuan, up 1.18 percent year-on-year.Comm Pharmaceuticals: China's pharmaceutical sector revenue reached 12 billion
in early July, the 2017 China Pharmaceutical Industry Top 100 list, Kangmei Pharmaceuticals ranked eighth, the annual report data show that the company's total revenue in 2017 reached 26.477 billion yuan, net profit of 4.101 billion yuan. Chinese medicine sector is the company's current operating income accounted for the highest proportion of the business sector, of which Chinese medicine beverage tablets business in the industry in a leading position, production and marketing scale ranked first; Data for 2017 show that Kangmei Pharmaceuticals' total revenue from the trade in Chinese medicine tablets and Chinese herbal medicines amounted to 12 billion yuan.
Kangmei Pharmaceuticals, as a leading enterprise in the Chinese medicine beverage tablet industry, has seen rapid growth in the business revenue of Chinese medicine drink tablets in recent years, reaching a new level every year, with gross margins maintaining at about 34% to 35%.
In recent years, the national level of the Chinese medicine beverage tablet industry more stringent supervision, industry concentration has been improved, Kangmei Pharmaceuticals has built an integrated business system of the Chinese medicine industry chain, in the upstream formation of the chinese medicine supply core resources, effectively guarantee the quality and traceability of Chinese medicine tablets, in line with industry trends and regulatory direction, the future development potential is huge.
in recent years, Kangmei Pharmaceuticals has set up a modern pharmaceutical logistics system and in the downstream formation of medical institutions resources, pharmacy custody, smart pharmacy, OTC retail, pharmacy chain, direct marketing, pharmaceutical e-commerce, mobile medical in one of the all-round multi-level marketing network, is conducive to the company to play a synergistic advantage to reduce comprehensive operating costs, in a relatively short period of time to play channel advantages to form the digestion of new capacity, thereby rapidly expanding the scale of Chinese medicine and beverage business, improve market share.
by the market supply and demand, planting area increase or decrease, yield abundance, climate change, natural disasters, man-made speculation and other factors, in recent years, some of the prices of medicinal herbs there are certain fluctuations.
In order to improve the company's market share in the trading business of Chinese herbal medicine, strengthen the initiative of upstream raw materials supply and access to more information channels, in recent years, Kangmei Pharmaceuticals has acquired several major domestic professional market for Chinese herbal medicines, combined with the independent development of the Chinese medicine flow system, the company's industrial chain circulation system has gradually become a scale and brand effect, and gradually mastered the Chinese herbal medicine market, information, prices and other aspects of the initiative. In fiscal 2017, Kangmei Pharmaceuticals' trade in Chinese herbal medicines has reached more than 138 varieties, and gross margin has gradually increased.More than 3 billion, including the entire industrial chain of Chinese medicine
According to the listed company announcement rough statistics, as of July 27, 2018, Kangmei Pharmaceuticals issued six related announcements on investment in Chinese medicine business, including investment in the opening of four subsidiaries to develop the cultivation business of medicinal herbs, investment in the opening of two subsidiaries to develop the trade in medicinal herbs, investment in the development of research institutes to carry out research and development of Chinese medicine, and two major industrial park projects have attracted much attention, the investment amount of these two industrial parks are more than 1 billion yuan.The investment amount of the two industrial parks is more than 1 billion, "the kingdom of Traditional Chinese medicine" more and more solid
on July 3, Kangmei Pharmaceuticals announced that, according to the company's overall development strategy plan and market demand, in order to further improve the company's Chinese medicine tablets, health food sector Production capacity, to meet the company's industrial chain terminal smart pharmacy, smart medicine cabinet and other channels of sales needs, enhance the company's core competitiveness, the company intends to invest 140 million yuan in Kunming City, Yunnan Province, the construction of Kangmei Kunming Great Health Industrial Park project, the total planning area of about 350 acres.
project construction content covers the manufacture and production of Chinese medicine tablets, health food, preparations, the construction of regional preparation center, and the construction of storage logistics center, will be based in Kunming, facing the southwest, to create a centralized pharmaceutical manufacturing, warehouse distribution, pharmaceutical integrated services as one of the ecological, intensive, professional modern pharmaceutical and health industrial park. The construction period of the project is 3 years, and the funds required for the project are self-financing by the company.
that after the completion of the project will greatly improve the company's economic efficiency and comprehensive competitiveness, Chinese medicine added an annual output value of about 268 million yuan, to achieve sustainable and rapid development. At present, the planning project has passed the consideration of the company's general meeting of shareholders.
July 3, Kangmei Pharmaceuticals issued another announcement, in order to further expand the company's Chinese medicine tablets, health food production capacity, improve product quality, improve product structure, expand the hospital pharmacy, smart pharmacy, pharmacy chain business, to meet market demand, the company It is proposed to invest 160 million yuan in the construction of the Chinese medicine industrial park project in Puning, the construction of a "research and development, production, logistics and distribution, supporting services in one" integrated Chinese medicine industrial park, the total planning area of the project is about 332 acres. The construction period of the project is 3 years, and the source of funds is self-financing by the company.
Comme Pharmaceuticals said that the construction of this project is mainly to expand the company's Chinese medicine tablets, health food production capacity, improve the company's logistics services capacity, give full play to the company's entire industrial chain advantages, combined with the city of Puning Chinese medicine resources, to build Puning City's largest Chinese medicine tablets and health care products industrial park. After the completion of the project will be conducive to enrich the company's Chinese medicine tablet product category, expand the market share of Chinese medicine tablets, for the company's entire industrial chain downstream smart pharmacy, smart medicine cabinet and other pharmaceutical services to lay a solid foundation, it is expected that the project will have a positive impact on the company's performance growth. At present, the planning project has passed the consideration of the company's general meeting of shareholders.conclusion
Kangmei Pharmaceuticals, as a leading enterprise of Chinese medicine drink tablets, continues to optimize all aspects of the whole industrial chain of Chinese medicine, and move forward. In 2018, Kangmei Pharmaceuticals will further strengthen the strategic layout of Chinese medicine resources in the Chinese medicine sector, forming a Chinese herbal medicine planting system based on seed seedling, with the cultivation of Chinese herbal medicines as the core, and the construction of the initial processing and traceability system of Taodo herbal medicines as the support. Explore sustainable, scalable and replicable innovation models for poverty alleviation in the Chinese herbal medicine cultivation industry. We will promote the construction and application of capacity adjustment models, strengthen the integrated mechanism of internal supply chain, and continuously optimize the market demand-oriented planning system. Strengthen upstream control capabilities, deeply dock downstream terminals, introduce blockchain technology, and build a supply chain alliance for Chinese medicine. (Mi Net)